Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Aardvark Therapeutics, Inc. alleging securities fraud related to its February 2025 IPO and subsequent period through May 2026. The complaint claims the company made materially false and misleading statements about the safety and prospects of its drug candidate ARD-101, and that offering documents were negligently prepared. Investors who purchased shares during the class period are encouraged to join the lawsuit.